growth revenu anticip
maintain sell rate upgrad tp
estim tp base
forward price-to-earnings multipl adjust ep
provid upsid potenti
expect top-lin revenu declin
expect revenu increas due increas
product sale compani come year
product like yescarta biktarvi
estim base follow factor declin
revenu earn lower hcv sale year
growth new product launch like biktarvi yescarta
gilead revenu declin due
lower sale hcv product estim
non-gaap declin
estim
ep includ unfavor impact
per share impair non-cash tax charg
relat intang asset acquir kite pharma inc
kite non-gaap ep compar
mn except ep crispidea name tickergildstock ratingsellunchangedindustri viewoverweightpositivepric may week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth may
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
yescarta axicabtagen ciloleucel launch
unit state octob gener
sale sale
hiv product sale compar
increas due launch biktarvi
continu uptak descovi genvoya
odefsey
cell therapi gilead made tremend progress
number center author saw steadi
measur adopt yescarta
approv yescarta europ
gilead announc immuno-oncolog partnership
agenu inc focus develop
commerci novel immuno-oncolog therapi
gilead announc strateg collabor scholar
hold corpor discov develop highli
specif inhibitor transform growth factor beta
activ treatment fibrot diseas
gilead announc global strateg collabor
tango inc discov develop
commerci pipelin innov target immuno-
oncolog treatment patient cancer
gilead gener cash oper
gilead repaid debt major
relat acquisit kite paid cash
dividend gilead repurchas
share
gilead advanc pipelin finish year
strong balanc sheet expect enabl
continu execut partnership drive
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend yield n/a pay-out dividend date ex-dividend date last split factor new per last split date jan inform gilead scienc inc may
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research sale gener total oper oper interest incom incom provis incom net incom continu net incom avail common weight averag share estim annual actual annual actual quarterli may
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item gilead scienc inc may
provid oper activ decreas compar due
lower cash receipt result lower product sale higher tax payment
provid invest activ compar cash use invest
activ chang due higher proce matur market
debt secur lower purchas market debt secur
use financ activ compar cash provid financ
activ chang due higher repay debt repurchas common
stock
defer incom oper increas decreas increas decreas current assets- decreas increas decreas increas current decreas increas work capital- non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant equipment- acquisitions- net invest financ activitiesissu debt- issuanc capit repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end may
gilead earn revenu declin quarter due declin
gilead revenu decreas compar
total product revenu declin
compar
cog increas compar
non-gaap cog increas
compar cog non-gaap cog increas
due reserv excess raw materi inventori
inventori reserv per dilut share
record excess raw materi due sustain decreas demand
product gross margin decreas compar
non-gaap product gross margin decreas
compar
 expens increas
compar expens increas due
impair charg relat in-process ipr kite-
program anti-bcma evalu treatment multipl
myeloma up-front collabor expens higher invest
support growth gilead busi follow acquisit kite
partial off-set gilead purchas cell design lab inc
non-gaap expens increas
compar non-gaap expens increas due
higher invest support growth gilead busi follow
acquisit kite
decreas
compar
increas
compar
sg expens increas compar
sg expens decreas due lower stock-bas
compens expens associ acquisit kite partial off-set
higher invest support growth gilead busi follow
acquisit kite
non-gaap sg expens increas
compar non-gaap expens increas due
higher invest support growth gilead busi follow
acquisit kite
incom expens decreas compar
interest expens compar
provis incom tax
compar effect tax rate
compar
net incom compar net loss
non-gaap net incom compar
gaap ep flat compar
non-gaap ep declin compar
ep includ unfavor impact
impair non-cash tax charg relat intang asset acquir
kite pharma inc kite
increas
compar
non-gaap ep declin
compar
total revenu declin compar
decreas due lower sale hcv product
total product sale declin compar
royalti contract revenu
compar
cog increas
compar
cog increas compar
non-gaap cog increas compar
compar
cog increas due reserv excess raw materi inventori cog also
increas due amort expens relat intang asset acquir
connect gilead acquisit kite
product gross margin compar non-
product gross margin compar
 expens increas compar
non-gaap expens increas
compar
 expens increas due impair charg relat
ipr program up-front collabor expens full year
invest support growth gilead busi follow
acquisit kite higher stock-bas compens expens associ
acquisit kite
sg expens increas compar
non-gaap sg expens increas
compar
sg expens increas due full year invest support
growth gilead busi follow acquisit kite partial off-set
lower acquisition-rel cost associ acquisit kite
incom expens net increas compar
interest expens compar
non-gaap tax rate compar
net incom increas
compar
net incom increas compar
non-gaap net incom decreas
compar
declin
compar
gaap ep increas compar
non-gaap ep decreas compar
gilead portfolio market product includ ambisom atripla
stribild truvada tybost vemlidi viread vosevi yescarta
gilead intern commerci sale oper market
subsidiari countri gilead also sell distribut certain
product corpor partner royalty-pay collabor
total product revenu declin compar
total product sale increas
compar due lower sale hcv product
product sale unit state europ
locat product sale
unit state europ locat
product sale unit state decreas due lower sale hcv
product partial off-set higher sale hiv product product sale
europ decreas due lower sale hcv product avail
gener version truvada atripla viread
product sale intern locat decreas due lower sale
hcv product japan sale hcv product japan decreas
compar due lower market
share result increas competit
hcv product sale consist epclusa harvoni vosevi sovaldi hiv
product sale compar
hiv product sale compar
increas due lower averag net sell price lower sale
volum across major market result increas competit
epclusa sale declin compar
epclusa sale declin
compar
epclusa sale declin
compar epclusa sale europ declin
compar epclusa sale
locat increas compar
harvoni sale declin compar
harvoni sale declin
compar
increas
compar
harvoni sale declin
compar
harvoni sale declin
compar harvoni sale europ declin
compar harvoni sale
locat declin compar
vosevi sale increas compar
total sale declin
compar
vosevi sale increas
compar total revenu europ increas
compar total revenu
locat increas compar
hiv product sale increas compar
hiv product sale increas
compar increas due launch
biktarvi continu uptak descovi genvoya odefsey
hiv product sale increas
compar total revenu europ decreas
compar total revenu
locat decreas compar
increas
compar
product sale descovi
increas
compar
descovi ftc/taf -base product biktarvi descovi genvoya
product sale descovi ftc/taf -base product increas
compar sale
increas compar
sale descovi ftc/taf -base product increas
compar total sale
europ increas compar
total revenu locat increas
compar
biktarvi sale total
sale total
sale europ total
sale locat
genvoya sale increas compar
genvoya sale increas
compar total sale increas
compar total sale
europ increas compar
total sale locat compar
odefsey sale increas compar
odefsey sale increas
compar total sale increas
compar total sale europ
increas compar total sale
locat compar
biktarvi sale
odefsey sale increas
compar
atripla sale declin
compar
stribild sale declin
compar
truvada ftc/tdf -base product atripla complera/eviplera stribild
product sale truvada increas
compar total product sale increas
compar
sale truvada increas compar
total sale europ decreas
compar total sale locat
compar
atripla sale declin compar
total sale declin
compar total sale decreas
compar total sale europ
decreas compar total
sale locat decreas compar
complera/eviplera sale declin
compar total sale declin
compar total sale
 decreas compar total
sale europ decreas compar
total sale locat compar
stribild sale declin compar
total sale declin
compar total sale declin
compar total sale
europ decreas compar
total sale locat compar
product sale includ product hbv cardiovascular
oncolog categori inclus vemlidi viread letairi ranexa
zydelig ambisom decreas compar
sale viread
use treatment
decreas due
avail gener
version product
sale viread use treatment chronic hbv infect
decreas due avail gener version product
letairi expect face gener competit unit state
 patent ambrisentan activ pharmaceut
ingredi letairi expir juli
ranexa also expect face gener competit unit state
gilead expect declin letairi ranexa sale unit state
gener entri
yescarta gener sale compar sale
sale
compar sale
gilead announc
china treatment
hcv genotyp
infect adult
adolesc age
product pipelin updat
product pipelin updat announc gilead
hiv liver diseas program
gilead announc china nation medic product
administr nmpa approv harvoni china treatment
hcv genotyp infect adult adolesc age year
gilead announc nmpa approv descovi china
treatment infect adult adolesc
gilead announc nmpa approv vemlidi china
treatment chronic hbv infect adult adolesc
gilead present data liver meet includ
announc
result studi investig epclusa hcv infect patient
sever renal impair undergo dialysi harvoni pediatr
hcv patient age three five year ad efficaci safeti
profil sofosbuvir-bas regimen across divers patient popul
result gilead hbv cure develop program
result gilead clinic develop program advanc fibrosi
due nonalcohol steatohepat data present support on-going
develop gilead investig compound evalu util
non-invasive test identif patient advanc
fibrosi demonstr signific burden diseas affect
result demonstr treatment investig
select nonsteroid farnesoid receptor agonist led signific
improv liver biochemistri marker cholestasi
patient primari scleros cholang
product pipelin updat
product pipelin updat announc gilead
oncolog cell therapi program
present data annual meet american societi
hematolog includ announc
updat result single-arm phase studi evalu
formerli investig chimer antigen
receptor cell therapi adult patient relaps refractori
acut lymphoblast leukemia median follow-up month
follow singl infus evalu patient
achiev complet tumor remiss defin complet remiss cr
cr incomplet hematolog recoveri rate undetect
minim residu diseas patient achiev complet tumor
remiss
two-year efficaci safeti data pivot trial
yescarta patient refractori larg b-cell lymphoma
minimum follow-up two year singl infus yescarta
median follow month patient on-going
efficaci safeti data
pivot
trial yescarta patient
refractori larg b-cell
discov phase
studi prep
pipelin mileston anticip
descovi primari endpoint data discov phase studi
vesatolimod complet phase studi hiv cure
capsid inhibitor data phase studi
nrti data phase studi
week data atla
phase studi
firsocostat
patient advanc
fibrosi due nash
product pipelin updat
pipelin mileston anticip
nash dkd pbc psc
data stellar phase studi nash
data stellar phase studi nash
initi phase studi diabet kidney diseas
data phase nash psc
interim data phase pbc
initi phase studi psc
data atla phase studi selonsertib and/or cilofexor
and/or firsocostat patient advanc fibrosi due nash
data phase studi
data phase studi cutan lupu erythematosu
data phase studi sjogren syndrom
product pipelin updat
pipelin mileston anticip
complet enrol select phase studi uc
enrol select
phase studi uc
data finch phase studi ra
data finch phase studi ra
data select phase studi uc
complet enrol divers phase studi crohn diseas
initi phase studi uc
remdesivir complet enrol phase studi ebola
complet enrol
phase studi ebola
present follow data
initi phase combin studi agonist
complet enrol pivot phase indol nhl
initi phase line high risk dlbcl
product pipelin updat
pipelin mileston anticip
enrol phase
complet enrol pivot phase line dlbcl
initi phase combin studi rituximab enalidomid zuma-
endpoint phase
combin studi r/r
initi pivot phase pediatr
initi phase cll
complet enrol pivot phase adult
file fda regulatori approv mcl
complet enrol phase mage solid tumor
file ind tcr target solid tumor
file ind allogen
achiev first endpoint phase combin studi r/r cll
tabl show pipelin product candid gilead
tabl show pipelin product candid gilead
trialind areaiiiiiihematology/oncologyaxicabtagen nhldlbcl line dlbcldlbcl line allpediatr mage tumortirabrutinib btk inhibitor b-cell malignanciesphas guidanc product sale
reflect anticip
entri gener version
letairi ranexa
unit state full
year impact gener
fumar certain
guidanc conclus
guidanc product sale reflect anticip entri gener
version letairi ranexa unit state full year impact
gener product contain tenofovir disoproxil fumar certain european
countri dilut ep impact acquisition-rel up-front collabor
stock-bas compens expens
gilead revenu declin due lower sale
hcv product non-gaap declin
gaap ep includ unfavor impact per share
impair non-cash tax charg relat intang asset acquir
kite pharma inc kite non-gaap ep
compar
gilead grow momentum hiv franchis due
continu strong uptak descovi portfolio biktarvi sale truvada
prep use individu
gilead repurchas share result reduct
dilut share outstand year end gilead dividend increas
gilead continu execut maxim opportun hcv
initi plan launch author gener year keep us
competit durabl long-term market gilead advanc pipelin
finish year strong balanc sheet enabl
continu execut partnership drive futur growth
non- reconcili
non- reconcili
non- reconcili
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin decreas compar due increas cog
oper margin declin compar due increas expens
net margin increas compar due decreas tax rate
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth gilead scienc inc may
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale gilead scienc inc may
invest flow
sale
mrq ratio growth yoy oper growth yoy free growth mrqyoy growth revenu growthoper incom growthep mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset gilead scienc inc may
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item gilead scienc inc may
balanc sheet ratio
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas business- sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc net chang capit free may
current price-to-earnings price-to-earnings trade averag price-to-earnings
sinc may near may expect forward price-to-earnings
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvalueblackrock vanguard group inc capit research global northern trust geod capit manag dodg cox capit world top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard invest compani spdr etf vanguard institut fund-institut amcap etf tr- qqq tr seri dodg cox stock growth fund america american mutual fund may
developmentsgilead scienc novo nordisk announc intent initi clinic collabor nashapril scienc inc andnovo nordisk a/sannounc compani intend collabor clinic trial combin compound respect pipelin nonalcohol steatohepat nash intend clinic trial proof concept studi combin novo nordisk semaglutid analogu gilead cilofexor fxr agonist firsocostat inhibitor treatment patient nash compani also explor potenti collabor preclin research advanc understand diseas gilead submit supplement new drug applic food drug administr once-daili descovi hiv pre-exposur prophylaxisapril scienc inc announc compani submit supplement new drug applic snda theu food drug administr fda descovi emtricitabin mg tenofovir alafenamid mg tablet pre-exposur prophylaxi prep reduc risk sexual acquir infect among individu hiv-neg risk hiv prioriti review voucher submit file lead anticip review time six month gilead galapago announc filgotinib meet primari endpoint phase finch studi methotrexate-nav rheumatoid arthriti patientsmarch scienc inc andgalapago nvannounc week result finch on-going random double-blind active-control phase studi filgotinib investig oral select inhibitor adult moderately-to-sever activ rheumatoid arthriti finch evalu filgotinib combin methotrex monotherapi -nave patient studi achiev primari endpoint proport patient achiev anamerican colleg percent respons week proport patient achiev primari endpoint respons week significantli higher filgotinib mg plu filgotinib mg plu compar alon gilead scienc launch posit initi address uniqu challeng age popul live hivfebruari scienc inc announc grant organ inth unit statesthrough gilead hiv posit initi effort aim enhanc live individu age hiv focus three prioriti area improv care coordin increas resourc better well-b educ inform polici impact peopl live age hiv estim suggest percent peopl live hiv face least one age-rel medic condit compar percent gilead scienc inc may
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit gilead scienc inc may
consensu view analyst trend stock
compar
forward price-to-earnings
compar
 average
annual usdgrowth high day day day estim avgfive-year growth forecast comparisongildindustri avg avgprice/earn yield may
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth current qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate gilead scienc inc may
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price show huge fluctuat quarter dip march
stock price declin period
stock price volatil year declin year
rang stock
stock price volatil past due poor perform busi
stock price declin past
gilead revenu declin due lower product sale hcv product saw
strong perform hiv product yescarta biktarvi saw strong growth sinc launch
expect see growth futur well therefor expect growth revenu
recommend sell rate tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
